Article
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Blood - 15 Oct 2008
Young Ken H, Leroy Karen, Møller Michael B, Colleoni Gisele W B, Sánchez-Beato Margarita, Kerbauy Fábio R, Haioun Corinne, Eickhoff Jens C, Young Allen H, Gaulard Philippe, Piris Miguel A, Oberley Terry D, Rehrauer William M, Kahl Brad S, Malter James S, Campo Elias, Delabie Jan, Gascoyne Randy D, Rosenwald Andreas, Rimsza Lisa, Huang James, Braziel Rita M, Jaffe Elaine S, Wilson Wyndham H, Staudt Louis M, Vose Julie M, Chan Wing C, Weisenburger Dennis D, Greiner Timothy C
Abstract excerpt
The purpose of this study is to correlate the presence of TP53 gene mutations with the clinical outcome of a cohort of patients with diffuse large B-cell lymphoma (DLBCL) assembled from 12 medical centers. TP53 mutations were identified in 102 of 477 patients, and the overall survival (OS) of patients with TP53 mutations was significantly worse than those with wild-type TP53 (P < .001). However, subsets of TP53...
Topics
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Cyclophosphamide
- DNA Mutational Analysis
- Doxorubicin
- Exons
- Female
- Humans